Tissue marking implant

Information

  • Patent Grant
  • 8668737
  • Patent Number
    8,668,737
  • Date Filed
    Wednesday, March 21, 2012
    12 years ago
  • Date Issued
    Tuesday, March 11, 2014
    10 years ago
Abstract
An implant for marking an area within a living body includes a matrix material and a marking material. The implant is formable to fit the shape and size of a cavity in the human body. The implant is configured to support tissue surrounding the cavity and to allow in-growth of fibrous tissue into and replace at least a portion of the matrix material.
Description
BACKGROUND OF THE INVENTION

1. Field of the Invention


The present invention relates to implantable prostheses. More particularly, the present invention relates to implantable breast prostheses designed to eliminate encapsulation and reduce scarring, and to replace tissue removed for purposes of biopsy or lumpectomy.


2. Description of the Related Art


Breast prostheses are utilized for augmentation mammoplasty and in cosmetic surgery. Prostheses are also indicated in breast cancer surgery, such as lumpectomies, where a portion of the breast is removed and can leave some disfigurement if not replaced by a similar amount of tissue and/or augmentation material.


Similarly, biopsies can leave small dimples or imperfections if remedial steps are not taken. About 1 million breast biopsies are performed in the United States annually. As a result, some 200,000 new breast cancers are diagnosed each year.


Known methods of augmentation mammoplasty utilize silicone or saline implants. These methods have been complicated post-operatively by encapsulation of the implants, which can occur to varying degrees. Encapsulation produces a hard area of scar tissue around the implant, resulting in a rigid, abnormally-shaped mount beneath the breast tissue or pectoralis muscle, depending upon the placement of the implant.


Moreover, the known implant materials may not be indicated for replacement of smaller amounts of tissue, as would be required to prevent dimpling after biopsies, for example. Further, the known implant materials are not amenable to resizing. In addition, known implants are not capable of being implanted through a cannula or needle, and are not readily instilled with medicaments or chemical agents that would be useful in treating the patient.


Accordingly, a need exists for implants and methods that can be adapted for replacement of small as well as large amounts of tissue. A need also exists for implants that can be delivered through cannulae or needles, as well as being able to significantly reduce or eliminate encapsulation, resulting in a prolonged, aesthetically pleasing, soft mound below the breast tissue or pectoralis muscle. In addition, a need exists for implants into which useful substances, such as beneficial medications, chemical agents, hormonal treatments, stem cells, such as adipocytes, cellular precursors and components, and radiation media can be instilled to enhance the treatment capabilities of the implant in cancer and other breast pathology.


BRIEF SUMMARY OF THE INVENTION

The present invention overcomes deficiency of the prior art, such as those noted above, by providing an implant in which at least the outer portion of the implant, and as much as the entire implant, is made of a resorbable material. The implant is sized and shaped to reduce excised tissue. Preferably, the implant provides a support structure in the form of a framework or scaffold for the surrounding tissue after implantation. The support structure preferably is porous to permit the in-growth of fibrous replacement tissue. Advantageously, replacement tissue in-growth takes place without encapsulation and with reduced scarring.


The invention, in one form thereof, is directed to an implant for marking an area within a living body. The implant includes a matrix material and a marking material. The implant is formable to fit the shape and size of a cavity in the human body. The implant is configured to support tissue surrounding the cavity and to allow in-growth of fibrous tissue into and replace at least a portion of the matrix material.


The invention, in another form thereof, is directed to a tissue marking implant. The tissue marking implant includes a matrix and a dye marker. A matrix is collagen material. The matrix has a porous structure for supporting surrounding tissue of a breast and is configured to provide a framework for the in-growth of fibrous tissue into the matrix. The dye marker is supported by the matrix for dispersion into the tissue.


According to an embodiment of the invention, excised tissue is replaced by installing an implant having at least an outer shell of resorbable material. The implant is sized and shaped to replace the excised tissue. The implant supports surrounding tissue while fibrous tissue replaces the resorbable portion of the implant.


In a further development, at least a portion of the implant can be provided in the form of a compressible or non-compressible sponge or foam, or a self-expanding sponge or foam. The sponge or foam provides a porous support matrix for surrounding and in-growing tissue. In the form of a compressible, expandable, or self-expanding sponge or foam, the implant advantageously can be inserted through a cannula or a needle, or optionally can be directly inserted. Additionally, the implant can be instilled with beneficial materials, such as indicated medicaments, therapeutics, or diagnostic agents, as well as matrix enhancing additives.


Other features and advantages of the present invention will become apparent from the following description of the invention which refers to the accompanying drawings.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 is a schematic elevation of a breast implant according to a preferred embodiment of the present invention.



FIG. 2 is a schematic sectional view of a breast after implantation of the implant of FIG. 1.



FIG. 3 is a schematic sectional view of a breast after implantation of an alternative embodiment of the implant of the present invention.



FIG. 4 is a schematic sectional view of a breast implant according to a second alternative embodiment of the present invention.



FIG. 5 is a schematic sectional view of a breast after implementation of the implant of FIG. 4.



FIG. 6 is a schematic sectional view of a breast implant and a method of insertion according to further alternative embodiments of the present invention, particularly for cases involving the removal of smaller pieces of tissue such as by biopsy and lumpectomy.





DETAILED DESCRIPTION OF THE INVENTION

Referring initially to FIGS. 1 and 2, an implant 2 has an outer shell 4 made of a biosorbable material woven into a mesh. The inner contents of the implant are fluids such as saline and autologous blood products.


Outer shell 4 is made entirely of biosorbable materials, such as collagens or polyglycolic acids, for example. Over a period of approximately three weeks to six months, the outer shell dissolves, leaving the inner contents 6 present inside the breast. Hard encapsulation will not occur because there is not a foreign body contained within the prosthetic space.


Referring to FIG. 3, implantation of an alternative embodiment of implant 2 is illustrated in which the outer shell 4 includes both biosorbable material, and nonabsorbable material, such as monofilament polypropylene fibers. Outer shell 4 is provided as a mesh or weave of the mixed material, surrounding contents 6 as described above. After a resorption period, contents 6 remain surrounded by a skeletal outer shell made up of non-absorbable fibers 8.


Advantageously, the proportions and spacing of the two types of materials can be altered to provide the desired properties of containment using a minimal amount of nonabsorbable material. Accordingly, the non-absorbable fibers 8 which remain after the biosorbable materials resorb will act as a scaffolding to allow the prosthesis to hold its shape; however, because of the limited amount of foreign material, encapsulation and scarring are decreased.


Referring to FIGS. 4 and 5, a second alternative embodiment of the present invention is shown. A prosthesis 10 features two capsules, a larger, outer capsule 12 made of biosorbable materials, and a smaller inner capsule 14 made of anon-absorbable material. Inner capsule 14 also can be made partially resorbable as in the first alternative embodiment above. Outer capsule 12 and inner capsule 14 can be separated by a thin layer 16 of saline or autologous fluids such as those described above. Inner capsule 14 surrounds a more permanent member 18 made of autologous fluids or saline, for example.


After implantation, outer capsule 12 dissolves, thus preventing hardening by encapsulation of the prosthesis. The supply of fluid 16 between the capsules (a few to several c.c.'s) is absorbed by the body once released by the dissolution of outer capsule 12.


Referring to FIG. 6, a further alternative embodiment of the present invention includes an implant prosthesis 20 provided in the form of a matrix framework, such as a sponge or foam. The implant, which preferably is entirely biodegradable (resorbable), has a porous structure which supports the surrounding tissue and provides a framework for the in-growth of fibrous tissue material. FIG. 6 illustrates tissue portion 24 surrounding implant 20 into which marker dye included in the implant, and described further below, has leached over time from the implant, thereby marking the tissue. Accordingly, a surgeon performing a subsequent procedure easily will recognize the tissue surrounding the previous excision.


According to a preferred embodiment, the implant is provided in the form of a foam or sponge which can be modified by a surgeon prior to implantation, such as at a lumpectomy or biopsy site, simply by trimming the sponge to the appropriate size and shape. Alternatively, the implant can be a pre-shaped prosthesis of appropriate size, or an appropriate amount of foam or foam-forming materials. Optionally, the foam can be provided as a self-expanding matrix that either is compressed, or forms in situ. Advantageously, the implant can be modified to correspond to the breast tissue that either has been removed, requires replacement, or requires augmentation. The foam or sponge matrix is sufficiently resilient to support the surrounding tissue without collapsing.


A preferred embodiment of implantation is illustrated schematically in FIG. 6, whereby the implant is elastically compressible, and is delivered using a cannula or needle 22 inserted into the breast. A single implant 20 is shown being compressed so as to fit within cannula 22. A force is applied to drive the compressed implant distally through and out the distal end of the cannula into the implant site, where the resilient implant 20 expands to fill the implant site space.


The force for advancing the sponge or foam material through the cannula can be applied directly to the implant, or indirectly using fluids, for example. Advantageously, the implant can be used in conjunction with stereotactic biopsy instrumentation, such as the ABBI® System, the MIB System by US Surgical, or the Mammotome® System by Johnson and Johnson.


As a further alternative, the sponge or foam implant of the present invention can form all or part of a larger implant, such as those described above. Accordingly, the tissue supporting sponge or foam or foam matrix will form, for example, all or part of the outer shell 4 of implant 2. Implantation using open procedures usually would be indicated when the sponge implant of the present invention is used as all or part of a larger implant. Accordingly, the sponge or implant would be placed directly into the biopsy or lumpectomy cavity.


In addition, the implant 20 can be provided in the form of a self-expanding foam, which can be injected through a tubular member 22 such as a needle or cannula in a metered amount. An appropriate amount of foam-forming materials can be inserted through cannula 22 and allowed to expand or form a matrix within the cavity created by the excised tissue. Alternatively, a specialized, applicator may be used to inject the desired amount of the foam. The amount of foam is preselected to allow sufficient expansion to fill the void left by the excision and support the surrounding tissue to prevent dimpling.


Following insertion of the implant, such as by an open method or one of the stereotactic methods described above, the resorbable implant occupies the breast tissue cavity and supports the surrounding tissue until such time as it resorbs or biodegrades. After initial implantation, the patient's own fluids, fibroblast, and stem cells, such adipocytes, vascular stem cells, and others, permeates the sponge prosthesis. In the case of a small implant, such permeation would occur naturally, subsequent to implantation. In the case of a larger implant, providing the implant at least partially filled with fluids prior to implantation may be indicated.


Advantageously, the new prosthesis decreases encapsulation after implantation. Various biosorbable materials can be used in the implant of the present invention. Known biosorbable materials include polyglycolic acid (Dexon, Davis & Geck); polyglactin material (Vicryl, Ethicon); poliglecaprone (Monocryl, Ethicon); and synthetic absorbable lactomer 9-1 (Polysorb, United States Surgical Corporation)


Other foamable materials that can be utilized in the present invention include, without limitation, proteins such as collagen, fibronectin, laminin and fibrin, most preferably collagen, and high molecular weight polysaccharides, such as heparan sulphate, chondroitin sulphate, hyaluronic acid and dermatan sulphate. Mixtures of any of the aforementioned materials also can be used, as required.


The materials can be modified, by cross-linking for example, to control degradation rates over varying lengths of time, after which they are substantially or completely resorbed.


Foams can be formed by various means known to those skilled in the art, including injecting an aerosol into a gel, and freeze-drying aqueous dispersions of the foam-forming material. Foaming agents can be included to promote formation of the foam. In addition, stabilizing agents can be included to enhance foam stability. The foams can be extruded or formed in situ.


According to the present invention, these products may be mixed with one another or combined to provide various resorption times or gradients, and/or may be interrelated with non-absorbable materials, such as polypropylene or PTFE (polytetrafluoroethylene) sold as (Gore-Tex®) material, for example. In an instance where a non-absorbable material is utilized, the non-resorbable implant section will remain partially intact as a permanent structure.


In each of the embodiment, the resorbable portions of the prosthesis ultimately biodegrades, and the patient is left with autologous tissue, some of which may have been implanted, or a permanent implant such as saline, as a filler for the biopsy cavity, thus preserving the contour of the breast and preventing indentation of the overlying skin.


The implants of the present invention further can be instilled, before or after implantation, with indicated medicines and other chemical or diagnostic agents. Examples of such agents include, but are not limited to, antibiotics, chemotherapies, other cancer therapies, brachytherapeutic material for local radiation effect, x-ray opaque or metallic material for identification of the area, hemostatic material for control of bleeding, growth factor hormones, immune system factors, gene therapies, biochemical indicators or vectors, and other types of therapeutic or diagnostic materials which may enhance the treatment of the patient.


The breast implant preferably includes a permanent or temporary dye marker such as, but not limited to, indigo carmine or methylene blue. This marker serves as a visual identification of the area that has been biopsied or a lumpectomy has been performed so that in the future an operating surgeon can identify the surrounding tissue before he violates the previously biopsied cavity. These dyes leach into the breast tissue giving the surgeon an indication when he is nearing the point of interest, that being a previous biopsy site particularly if it is positive for a cancer or if it is a site for which a lumpectomy has been previously performed and the pathologist advises us that there is residual cancer. The surgeon can thus remove any of the surrounding breast tissue that contains dye and depending upon its concentration and the distance that it has traveled from the biopsy site will give us an indication of how much tissue should appropriately be removed.


This dye may be integrated with a bioabsorbable material such as, but not limited to collagen or may be in a separate capsule that is inserted with the bioabsorbable material as well as a metallic device for radiographic identification.


These two dyes are very dark colored dyes and these do leach through the breast tissue but will not stain the overlying skin.


The present invention has been described particularly in connection with a breast implant, but it will be obvious to those of skill in the art that the invention can have application to other parts of the body, such as the face, and generally to other soft tissue or bone. Accordingly, the invention is applicable to replacing missing or damaged soft tissue, structural tissue or bone, or for cosmetic tissue or bone replacement.


Although the present invention has been described in relation to particular embodiments thereof, many other variations and modifications and other uses will become apparent to those skilled in the art. It is preferred, therefore, that the present invention be limited not only by the specific disclosure herein, but only by the appended claims.

Claims
  • 1. An implant for marking an area within a surgically formed cavity in tissue of a living body comprising a matrix material and a marking material, the implant being formable to fit the shape and size of the surgically formed cavity in the tissue of the living body, the implant being configured to fill the surgically formed cavity in the tissue and support the tissue that surrounds the surgically formed cavity, and configured to allow in-growth of fibrous tissue into and replace at least a portion of the matrix material, wherein the matrix material comprises a foamed bioabsorbable protein.
  • 2. An implant for marking an area within a surgically formed cavity in tissue of a living body comprising a matrix material and a marking material, the implant being formable to fit the shape and size of the surgically formed cavity in the tissue of the living body, the implant being configured to fill the surgically formed cavity in the tissue and support the tissue that surrounds the surgically formed cavity, and configured to allow in-growth of fibrous tissue into and replace at least a portion of the matrix material, wherein the matrix material comprises a foamed collagen.
  • 3. A tissue marking implant for marking a breast cavity formed in a breast, comprising: a matrix having a porous structure configured to support surrounding tissue of the breast and configured to provide a framework for the in-growth of fibrous tissue into the matrix; anda dye marker supported by the matrix and configured for dispersion into the tissue surrounding the breast cavity.
  • 4. The tissue implant of claim 3, wherein the matrix comprises a collagen foam.
  • 5. The tissue implant of claim 3, wherein the matrix comprises a resilient framework for implantation with the matrix compressed into a volume smaller than the breast cavity, the resilient framework being configured to expand resiliently within the breast.
  • 6. The tissue implant of claim 3, wherein the matrix is self-expanding.
CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation of application Ser. No. 12/965,405, filed Dec. 10, 2010, now U.S. Pat. No. 8,157,862, which is a continuation of application Ser. No. 12/589,413, filed Oct. 23, 2009, now U.S. Pat. No. 7,871,438, which is a divisional of application Ser. No. 11/108,785, filed Apr. 19, 2005, now U.S. Pat. No. 7,637,948, which is a continuation-in-part of U.S. patent application Ser. No. 10/627,718, filed Jul. 28, 2003, now U.S. Pat. No. 6,881,226, which is a division of application Ser. No. 09/828,806, filed Apr. 10, 2001, now U.S. Pat. No. 6,638,308, which is a continuation in part of U.S. patent application Ser. No. 09/169,351, filed Oct. 9, 1998, now U.S. Pat. No. 6,214,045, which claims the benefit of U.S. Provisional Application Ser. No. 60/061,588, filed Oct. 10, 1997, U.S. Provisional Application Ser. No. 60/077,639, filed Mar. 11, 1998, and U.S. Provisional Application Ser. No. 60/091,306, filed Jun. 30, 1998, the disclosures of which are incorporated herein by reference.

US Referenced Citations (476)
Number Name Date Kind
2481408 Fuller et al. Sep 1949 A
2899362 Sieger, Jr. et al. Aug 1959 A
2907327 White Oct 1959 A
3341417 Sinaiko Sep 1967 A
3402712 Eisenhand Sep 1968 A
3516412 Ackerman Jun 1970 A
3593343 Viggers Jul 1971 A
3757781 Smart Sep 1973 A
3818894 Wichterle et al. Jun 1974 A
3823212 Chvapil Jul 1974 A
3921632 Bardani Nov 1975 A
4005699 Bucalo Feb 1977 A
4007732 Kvavle et al. Feb 1977 A
4041931 Elliott et al. Aug 1977 A
4103690 Harris Aug 1978 A
4105030 Kercso Aug 1978 A
4172449 LeRoy et al. Oct 1979 A
4197846 Bucalo Apr 1980 A
4217889 Radovan et al. Aug 1980 A
4276885 Tickner et al. Jul 1981 A
4294241 Miyata Oct 1981 A
4298998 Naficy Nov 1981 A
4331654 Morris May 1982 A
4390018 Zukowski Jun 1983 A
4400170 McNaughton et al. Aug 1983 A
4401124 Guess et al. Aug 1983 A
4405314 Cope Sep 1983 A
4428082 Naficy Jan 1984 A
4438253 Casey et al. Mar 1984 A
4442843 Rasor et al. Apr 1984 A
4470160 Cavon Sep 1984 A
4487209 Mehl Dec 1984 A
4545367 Tucci Oct 1985 A
4549560 Andis Oct 1985 A
4582061 Fry Apr 1986 A
4582640 Smestad et al. Apr 1986 A
4588395 Lemelson May 1986 A
4597753 Turley Jul 1986 A
4647480 Ahmed Mar 1987 A
4655226 Lee Apr 1987 A
4661103 Harman Apr 1987 A
4682606 DeCaprio Jul 1987 A
4693237 Hoffman et al. Sep 1987 A
4740208 Cavon Apr 1988 A
4762128 Rosenbluth Aug 1988 A
4813062 Gilpatrick Mar 1989 A
4820267 Harman Apr 1989 A
4832680 Haber et al. May 1989 A
4832686 Anderson May 1989 A
4847049 Yamamoto Jul 1989 A
4863470 Carter Sep 1989 A
4870966 Dellon et al. Oct 1989 A
4874376 Hawkins, Jr. Oct 1989 A
4889707 Day et al. Dec 1989 A
4909250 Smith Mar 1990 A
4938763 Dunn et al. Jul 1990 A
4950665 Floyd Aug 1990 A
4963150 Brauman Oct 1990 A
4970298 Silver et al. Nov 1990 A
4989608 Ratner Feb 1991 A
4994013 Suthanthiran et al. Feb 1991 A
4994028 Leonard et al. Feb 1991 A
5012818 Joishy May 1991 A
5059197 Urie et al. Oct 1991 A
5081997 Bosley, Jr. et al. Jan 1992 A
5120802 Mares et al. Jun 1992 A
5125413 Baran Jun 1992 A
5137928 Erbel et al. Aug 1992 A
5141748 Rizzo Aug 1992 A
5147307 Gluck Sep 1992 A
5147631 Glajch et al. Sep 1992 A
5162430 Rhee et al. Nov 1992 A
5163896 Suthanthiran et al. Nov 1992 A
5195540 Shiber Mar 1993 A
5197482 Rank et al. Mar 1993 A
5197846 Uno et al. Mar 1993 A
5199441 Hogle Apr 1993 A
5219339 Saito Jun 1993 A
5221269 Miller et al. Jun 1993 A
5231615 Endoh Jul 1993 A
5236410 Granov et al. Aug 1993 A
5242759 Hall Sep 1993 A
5250026 Ehrlich et al. Oct 1993 A
5271961 Mathiowitz et al. Dec 1993 A
5273532 Niezink et al. Dec 1993 A
5280788 Janes et al. Jan 1994 A
5281197 Arias et al. Jan 1994 A
5281408 Unger Jan 1994 A
5282781 Liprie Feb 1994 A
5284479 de Jong Feb 1994 A
5289831 Bosley Mar 1994 A
5320100 Herweck et al. Jun 1994 A
5320613 Houge et al. Jun 1994 A
5328955 Rhee et al. Jul 1994 A
5334381 Unger Aug 1994 A
5344640 Deutsch et al. Sep 1994 A
5353804 Kornberg et al. Oct 1994 A
5354623 Hall Oct 1994 A
5358514 Schulman et al. Oct 1994 A
5366756 Chesterfield et al. Nov 1994 A
5368030 Zinreich et al. Nov 1994 A
5388588 Nabai et al. Feb 1995 A
5394875 Lewis et al. Mar 1995 A
5395319 Hirsch et al. Mar 1995 A
5409004 Sloan Apr 1995 A
5417708 Hall et al. May 1995 A
5422730 Barlow et al. Jun 1995 A
5425366 Reinhardt et al. Jun 1995 A
5431639 Shaw Jul 1995 A
5433204 Olson Jul 1995 A
5449560 Antheunis et al. Sep 1995 A
5451406 Lawin et al. Sep 1995 A
5460182 Goodman et al. Oct 1995 A
5469847 Zinreich et al. Nov 1995 A
5475052 Rhee et al. Dec 1995 A
5490521 Davis et al. Feb 1996 A
5494030 Swartz et al. Feb 1996 A
5499989 LaBash Mar 1996 A
5507807 Shippert Apr 1996 A
5508021 Grinstaff et al. Apr 1996 A
5514085 Yoon May 1996 A
5522896 Prescott Jun 1996 A
5538726 Order Jul 1996 A
5542915 Edwards et al. Aug 1996 A
5549560 Van de Wijdeven Aug 1996 A
RE35391 Brauman Dec 1996 E
5580568 Greff et al. Dec 1996 A
5585112 Unger et al. Dec 1996 A
5611352 Kobren et al. Mar 1997 A
5626611 Liu et al. May 1997 A
5628781 Williams et al. May 1997 A
5629008 Lee May 1997 A
5636255 Ellis Jun 1997 A
5643246 Leeb et al. Jul 1997 A
5646146 Faarup et al. Jul 1997 A
5665092 Mangiardi et al. Sep 1997 A
5667767 Greff et al. Sep 1997 A
5669882 Pyles Sep 1997 A
5673841 Schulze et al. Oct 1997 A
5676146 Scarborough Oct 1997 A
5676925 Klaveness et al. Oct 1997 A
5688490 Tournier et al. Nov 1997 A
5690120 Jacobsen et al. Nov 1997 A
5695480 Evans et al. Dec 1997 A
5702128 Maxim et al. Dec 1997 A
5702716 Dunn et al. Dec 1997 A
5716981 Hunter et al. Feb 1998 A
5747060 Sackler et al. May 1998 A
5762903 Park et al. Jun 1998 A
5769086 Ritchart et al. Jun 1998 A
5776496 Violante et al. Jul 1998 A
5779647 Chau et al. Jul 1998 A
5782764 Werne Jul 1998 A
5782775 Milliman et al. Jul 1998 A
5795308 Russin Aug 1998 A
5799099 Wang et al. Aug 1998 A
5800362 Kobren et al. Sep 1998 A
5800389 Burney et al. Sep 1998 A
5800445 Ratcliff et al. Sep 1998 A
5800541 Rhee et al. Sep 1998 A
5817022 Vesely Oct 1998 A
5820918 Ronan et al. Oct 1998 A
5821184 Haines et al. Oct 1998 A
5823198 Jones et al. Oct 1998 A
5824042 Lombardi et al. Oct 1998 A
5824081 Knapp et al. Oct 1998 A
5826776 Schulze et al. Oct 1998 A
5830178 Jones et al. Nov 1998 A
5842477 Naughton et al. Dec 1998 A
5842999 Pruitt et al. Dec 1998 A
5845646 Lemelson Dec 1998 A
5846220 Elsberry Dec 1998 A
5851508 Greff et al. Dec 1998 A
5853366 Dowlatshahi Dec 1998 A
5865806 Howell Feb 1999 A
5869080 McGregor et al. Feb 1999 A
5871501 Leschinsky et al. Feb 1999 A
5876340 Tu et al. Mar 1999 A
5879357 Heaton et al. Mar 1999 A
5891558 Bell et al. Apr 1999 A
5897507 Kortenbach et al. Apr 1999 A
5902310 Foerster et al. May 1999 A
5911705 Howell Jun 1999 A
5916164 Fitzpatrick et al. Jun 1999 A
5921933 Sarkis et al. Jul 1999 A
5922024 Janzen et al. Jul 1999 A
5928626 Klaveness et al. Jul 1999 A
5928773 Andersen Jul 1999 A
5941439 Kammerer et al. Aug 1999 A
5941890 Voegele et al. Aug 1999 A
5942209 Leavitt et al. Aug 1999 A
5948425 Janzen et al. Sep 1999 A
5954670 Baker Sep 1999 A
5972817 Haines et al. Oct 1999 A
5980564 Stinson Nov 1999 A
5989265 Bouquet De La Joliniere et al. Nov 1999 A
6015541 Greff et al. Jan 2000 A
6030333 Sioshansi et al. Feb 2000 A
6053925 Barnhart Apr 2000 A
6056700 Burney et al. May 2000 A
6066122 Fisher May 2000 A
6066325 Wallace et al. May 2000 A
6071301 Cragg et al. Jun 2000 A
6071310 Picha et al. Jun 2000 A
6071496 Stein et al. Jun 2000 A
6090996 Li Jul 2000 A
6096065 Crowley Aug 2000 A
6096070 Ragheb et al. Aug 2000 A
6106473 Violante et al. Aug 2000 A
6117108 Woehr et al. Sep 2000 A
6120536 Ding et al. Sep 2000 A
6142955 Farascioni et al. Nov 2000 A
6159240 Sparer et al. Dec 2000 A
6159445 Klaveness et al. Dec 2000 A
6161034 Burbank et al. Dec 2000 A
6162192 Cragg et al. Dec 2000 A
6173715 Sinanan et al. Jan 2001 B1
6174330 Stinson Jan 2001 B1
6177062 Stein et al. Jan 2001 B1
6181960 Jensen et al. Jan 2001 B1
6183497 Sing et al. Feb 2001 B1
6190350 Davis et al. Feb 2001 B1
6190353 Makower et al. Feb 2001 B1
6200258 Slater et al. Mar 2001 B1
6203524 Burney et al. Mar 2001 B1
6203568 Lombardi et al. Mar 2001 B1
6213957 Milliman et al. Apr 2001 B1
6214045 Corbitt, Jr. et al. Apr 2001 B1
6214315 Greff et al. Apr 2001 B1
6220248 Voegele et al. Apr 2001 B1
6224630 Bao et al. May 2001 B1
6228049 Schroeder et al. May 2001 B1
6228055 Foerster et al. May 2001 B1
6231615 Preissman May 2001 B1
6234177 Barsch May 2001 B1
6241687 Voegele et al. Jun 2001 B1
6241734 Scribner et al. Jun 2001 B1
6251418 Ahern et al. Jun 2001 B1
6261243 Burney et al. Jul 2001 B1
6261302 Voegele et al. Jul 2001 B1
6264917 Klaveness et al. Jul 2001 B1
6270464 Fulton, III et al. Aug 2001 B1
6270472 Antaki et al. Aug 2001 B1
6287278 Woehr et al. Sep 2001 B1
6287332 Bolz et al. Sep 2001 B1
6289229 Crowley Sep 2001 B1
6306154 Hudson et al. Oct 2001 B1
6312429 Burbank et al. Nov 2001 B1
6316522 Loomis et al. Nov 2001 B1
6335029 Kamath et al. Jan 2002 B1
6336904 Nikolchev Jan 2002 B1
6340367 Stinson et al. Jan 2002 B1
6343227 Crowley Jan 2002 B1
6347240 Foley et al. Feb 2002 B1
6347241 Burbank et al. Feb 2002 B2
6350244 Fisher Feb 2002 B1
6350274 Li Feb 2002 B1
6354989 Nudeshima Mar 2002 B1
6356112 Tran et al. Mar 2002 B1
6356782 Sirimanne et al. Mar 2002 B1
6358217 Bourassa Mar 2002 B1
6363940 Krag Apr 2002 B1
6371904 Sirimanne et al. Apr 2002 B1
6394965 Klein May 2002 B1
6403758 Loomis Jun 2002 B1
6405733 Fogarty et al. Jun 2002 B1
6409742 Fulton, III et al. Jun 2002 B1
6424857 Henrichs et al. Jul 2002 B1
6425903 Voegele Jul 2002 B1
6436030 Rehil Aug 2002 B2
6450937 Mercereau et al. Sep 2002 B1
6450938 Miller Sep 2002 B1
6471700 Burbank et al. Oct 2002 B1
6478790 Bardani Nov 2002 B2
6506156 Jones et al. Jan 2003 B1
6511468 Cragg et al. Jan 2003 B1
6537193 Lennox Mar 2003 B1
6540981 Klaveness et al. Apr 2003 B2
6544185 Montegrande Apr 2003 B2
6551253 Worm et al. Apr 2003 B2
6554760 Lamoureux et al. Apr 2003 B2
6562317 Greff et al. May 2003 B2
6564806 Fogarty et al. May 2003 B1
6565551 Jones et al. May 2003 B1
6575888 Zamora et al. Jun 2003 B2
6575991 Chesbrough et al. Jun 2003 B1
6585773 Xie Jul 2003 B1
6605047 Zarins et al. Aug 2003 B2
6610026 Cragg et al. Aug 2003 B2
6613002 Clark et al. Sep 2003 B1
6616630 Woehr et al. Sep 2003 B1
6626850 Chau et al. Sep 2003 B1
6628982 Thomas et al. Sep 2003 B1
6636758 Sanchez et al. Oct 2003 B2
6638234 Burbank et al. Oct 2003 B2
6638308 Corbitt, Jr. et al. Oct 2003 B2
6652442 Gatto Nov 2003 B2
6656192 Espositio et al. Dec 2003 B2
6699205 Fulton, III et al. Mar 2004 B2
6712774 Voegele et al. Mar 2004 B2
6712836 Berg et al. Mar 2004 B1
6716444 Castro et al. Apr 2004 B1
6725083 De Santis et al. Apr 2004 B1
6730042 Fulton et al. May 2004 B2
6730044 Stephens et al. May 2004 B2
6746661 Kaplan Jun 2004 B2
6746773 Llanos et al. Jun 2004 B2
6752154 Fogarty et al. Jun 2004 B2
6766186 Hoyns et al. Jul 2004 B1
6774278 Ragheb et al. Aug 2004 B1
6780179 Lee et al. Aug 2004 B2
6824507 Miller Nov 2004 B2
6824527 Gollobin Nov 2004 B2
6846320 Ashby et al. Jan 2005 B2
6862470 Burbank et al. Mar 2005 B2
6863685 Davila et al. Mar 2005 B2
6881226 Corbitt et al. Apr 2005 B2
6899731 Li et al. May 2005 B2
6918927 Bates et al. Jul 2005 B2
6936014 Vetter et al. Aug 2005 B2
6939318 Stenzel Sep 2005 B2
6945973 Bray Sep 2005 B2
6951564 Espositio et al. Oct 2005 B2
6992233 Drake et al. Jan 2006 B2
6994712 Fisher et al. Feb 2006 B1
7001341 Gellman et al. Feb 2006 B2
7008382 Adams et al. Mar 2006 B2
7014610 Koulik Mar 2006 B2
7025765 Balbierz et al. Apr 2006 B2
7044957 Foerster et al. May 2006 B2
7083576 Zarins et al. Aug 2006 B2
7125397 Woehr et al. Oct 2006 B2
7160258 Imran et al. Jan 2007 B2
7172549 Slater et al. Feb 2007 B2
7214211 Woehr et al. May 2007 B2
7229417 Foerster et al. Jun 2007 B2
7236816 Kumar et al. Jun 2007 B2
7264613 Woehr et al. Sep 2007 B2
7294118 Saulenas et al. Nov 2007 B2
7297725 Winterton et al. Nov 2007 B2
7329402 Unger et al. Feb 2008 B2
7329414 Fisher et al. Feb 2008 B2
7416533 Gellman et al. Aug 2008 B2
7424320 Chesbrough et al. Sep 2008 B2
7449000 Adams et al. Nov 2008 B2
7527610 Erickson May 2009 B2
7534452 Chernomorsky et al. May 2009 B2
7569065 Chesbrough et al. Aug 2009 B2
7577473 Davis et al. Aug 2009 B2
7637948 Corbitt, Jr. Dec 2009 B2
7651505 Lubock et al. Jan 2010 B2
7819820 Field et al. Oct 2010 B2
7871438 Corbitt, Jr. Jan 2011 B2
7877133 Burbank et al. Jan 2011 B2
8157862 Corbitt, Jr. Apr 2012 B2
20010006616 Leavitt et al. Jul 2001 A1
20020004060 Heublein et al. Jan 2002 A1
20020016625 Falotico et al. Feb 2002 A1
20020022883 Burg Feb 2002 A1
20020026201 Foerster et al. Feb 2002 A1
20020035324 Sirimanne et al. Mar 2002 A1
20020045842 Van Bladel et al. Apr 2002 A1
20020052572 Franco et al. May 2002 A1
20020055731 Atala et al. May 2002 A1
20020058868 Hoshino et al. May 2002 A1
20020058882 Fulton, III et al. May 2002 A1
20020077687 Ahn Jun 2002 A1
20020082517 Klein Jun 2002 A1
20020082519 Miller et al. Jun 2002 A1
20020082682 Barclay et al. Jun 2002 A1
20020082683 Stinson et al. Jun 2002 A1
20020095204 Thompson et al. Jul 2002 A1
20020095205 Edwin et al. Jul 2002 A1
20020107437 Sirimanne et al. Aug 2002 A1
20020133148 Daniel et al. Sep 2002 A1
20020143359 Fulton, III et al. Oct 2002 A1
20020165608 Llanos et al. Nov 2002 A1
20020193815 Foerster et al. Dec 2002 A1
20020193867 Gladdish, Jr. et al. Dec 2002 A1
20030032969 Gannoe et al. Feb 2003 A1
20030036803 McGhan Feb 2003 A1
20030051735 Pavcnik et al. Mar 2003 A1
20030116806 Kato Jun 2003 A1
20030165478 Sokoll Sep 2003 A1
20030191355 Ferguson Oct 2003 A1
20030199887 Ferrera et al. Oct 2003 A1
20030225420 Wardle Dec 2003 A1
20030236573 Evans et al. Dec 2003 A1
20040001841 Nagavarapu et al. Jan 2004 A1
20040002650 Mandrusov et al. Jan 2004 A1
20040016195 Archuleta Jan 2004 A1
20040024304 Foerster et al. Feb 2004 A1
20040059341 Gellman et al. Mar 2004 A1
20040073107 Sioshansi et al. Apr 2004 A1
20040073284 Bates et al. Apr 2004 A1
20040097981 Selis May 2004 A1
20040101479 Burbank et al. May 2004 A1
20040101548 Pendharkar May 2004 A1
20040106891 Langan et al. Jun 2004 A1
20040116802 Jessop et al. Jun 2004 A1
20040124105 Seiler et al. Jul 2004 A1
20040127765 Seiler et al. Jul 2004 A1
20040133124 Bates et al. Jul 2004 A1
20040162574 Viola Aug 2004 A1
20040167619 Case et al. Aug 2004 A1
20040204660 Fulton et al. Oct 2004 A1
20040210208 Paul et al. Oct 2004 A1
20040213756 Michal et al. Oct 2004 A1
20040236212 Jones et al. Nov 2004 A1
20040236213 Jones et al. Nov 2004 A1
20050020916 MacFarlane et al. Jan 2005 A1
20050033157 Klein et al. Feb 2005 A1
20050033195 Fulton et al. Feb 2005 A1
20050036946 Pathak et al. Feb 2005 A1
20050045192 Fulton et al. Mar 2005 A1
20050059887 Mostafavi et al. Mar 2005 A1
20050059888 Sirimanne et al. Mar 2005 A1
20050065354 Roberts Mar 2005 A1
20050065453 Shabaz et al. Mar 2005 A1
20050080337 Sirimanne et al. Apr 2005 A1
20050080339 Sirimanne et al. Apr 2005 A1
20050085724 Sirimanne et al. Apr 2005 A1
20050100580 Osborne et al. May 2005 A1
20050113659 Pothier et al. May 2005 A1
20050119562 Jones et al. Jun 2005 A1
20050143650 Winkel Jun 2005 A1
20050165305 Foerster et al. Jul 2005 A1
20050175657 Hunter et al. Aug 2005 A1
20050181007 Hunter et al. Aug 2005 A1
20050187624 Corbitt, Jr. Aug 2005 A1
20050208122 Allen et al. Sep 2005 A1
20050234336 Beckman et al. Oct 2005 A1
20050268922 Conrad et al. Dec 2005 A1
20050273002 Goosen et al. Dec 2005 A1
20050277871 Selis Dec 2005 A1
20060004440 Stinson Jan 2006 A1
20060009800 Christianson et al. Jan 2006 A1
20060025677 Verard et al. Feb 2006 A1
20060036158 Field et al. Feb 2006 A1
20060036159 Sirimanne et al. Feb 2006 A1
20060074443 Foerster et al. Apr 2006 A1
20060079770 Sirimanne et al. Apr 2006 A1
20060079805 Miller et al. Apr 2006 A1
20060079829 Fulton et al. Apr 2006 A1
20060079888 Mulier et al. Apr 2006 A1
20060122503 Burbank et al. Jun 2006 A1
20060155190 Burbank et al. Jul 2006 A1
20060173280 Goosen et al. Aug 2006 A1
20060173296 Miller et al. Aug 2006 A1
20060177379 Asgari Aug 2006 A1
20060217635 McCombs et al. Sep 2006 A1
20060235298 Kotmel et al. Oct 2006 A1
20060241385 Dietz Oct 2006 A1
20070021642 Lamoureux et al. Jan 2007 A1
20070038145 Field Feb 2007 A1
20070057794 Gisselberg et al. Mar 2007 A1
20070083132 Sharrow Apr 2007 A1
20070135711 Chernomorsky et al. Jun 2007 A1
20070142725 Hardin et al. Jun 2007 A1
20070167736 Dietz et al. Jul 2007 A1
20070167749 Yarnall et al. Jul 2007 A1
20070239118 Ono et al. Oct 2007 A1
20070287933 Phan et al. Dec 2007 A1
20080091120 Fisher Apr 2008 A1
20080097199 Mullen Apr 2008 A1
20080188768 Zarins et al. Aug 2008 A1
20080269638 Cooke et al. Oct 2008 A1
20090000629 Hornscheidt et al. Jan 2009 A1
20090069713 Adams et al. Mar 2009 A1
20090076484 Fukaya Mar 2009 A1
20090131825 Burbank et al. May 2009 A1
20100121445 Corbitt, Jr. May 2010 A1
20110082547 Corbitt, Jr. Apr 2011 A1
20110184280 Jones et al. Jul 2011 A1
20120078092 Jones et al. Mar 2012 A1
20120116215 Jones et al. May 2012 A1
Foreign Referenced Citations (46)
Number Date Country
1029528 May 1958 DE
0146699 Jul 1985 EP
0255123 Feb 1988 EP
0292936 Nov 1988 EP
0458745 Nov 1991 EP
0475077 Mar 1992 EP
0552924 Jul 1993 EP
0769281 Apr 1997 EP
1114618 Jul 2001 EP
1163888 Dec 2001 EP
1281416 Jun 2002 EP
1364628 Nov 2003 EP
1493451 Jan 2005 EP
1767167 Mar 2007 EP
2646674 Nov 1990 FR
708148 Apr 1954 GB
2131757 May 1990 JP
8906978 Aug 1989 WO
9112823 Sep 1991 WO
9314712 Aug 1993 WO
9317671 Sep 1993 WO
9317718 Sep 1993 WO
9416647 Aug 1994 WO
9507057 Mar 1995 WO
9806346 Feb 1998 WO
9908607 Feb 1999 WO
9935966 Jul 1999 WO
9951143 Oct 1999 WO
0023124 Apr 2000 WO
0024332 May 2000 WO
0028554 May 2000 WO
0054689 Sep 2000 WO
0108578 Feb 2001 WO
0170114 Sep 2001 WO
0207786 Jan 2002 WO
0241786 May 2002 WO
03000308 Jan 2003 WO
2004045444 Jun 2004 WO
2005013832 Feb 2005 WO
2005089664 Sep 2005 WO
2006012630 Feb 2006 WO
2006056739 Jun 2006 WO
2006097331 Sep 2006 WO
2006105353 Oct 2006 WO
2007069105 Jun 2007 WO
2008077081 Jun 2008 WO
Non-Patent Literature Citations (12)
Entry
Armstong, J.S., et al., “Differential marking of Excision Planes in Screened Breast lesions by Organically Coloured Gelatins”, Journal of Clinical Pathology, Jul. 1990, No. 43 (7) pp. 604-607, XP000971447 abstract; tables 1,2.
Fucci, V., et al., “Large Bowel Transit Times Using Radioopaque Markers in Normal Cats”, J. of Am. Animal Hospital Assn., Nov.-Dec. 31, 1995 (6) 473-477.
Schindlbeck, N.E., et al., “Measurement of Colon Transit Time”, J. of Gastroenterology, No. 28, pp. 399-404, 1990.
Shiga, et al., Preparation of Poly(D, L-lactide) and Copoly(lactide-glycolide) Microspheres of Uniform Size, J. Pharm. Pharmacol. 1996 48:891-895.
Eiselt, P. et al, “Development of Technologies Aiding Large—Tissue Engineering”, Biotechnol. Prog., vol. 14, No. 1, pp. 134-140, 1998.
Press release for Biopsys Ethicon Endo-Surgery (Europe) GmbH; The Mammotome Vacuum Biopsy System. From: http://www.medicine-news.com/articles/devices/mammotome.html. 3 pages.
Johnson & Johnson: New Minimally Invasive Breast Biopsy Device Receives Marketing Clearance in Canada; Aug. 6, 1999. From http://www.jnjgateway.com. 4 pages.
Johnson & Johnson: Mammotome Hand Held Receives FDA Marketing Clearance for Minimally Invasive Breast Biopises; Sep. 1, 1999. From From http://www.jnjgateway.com. 5 pages.
Liberman, Laura, et al. Percutaneous Removal of Malignant Mammographic Lesions at Sterotactic Vacuum-assisted Biopsy. From: The Departments of Radiology, Pathology, and Surgery. Memorial Sloan-Kettering Cancer Center. From the 1997 RSNA scientific assembly. vol. 206, No. 3. pp. 711-715.
Fajardo, Laurie, et al., “Placement of Endovascular Embolization Microcoils to Localize the Site of Breast Lesions Removed at Stereotactic Core Biopsy”, Radiology, Jan. 1998, pp. 275-278, vol. 206-No. 1.
H. J. Gent, M.D., et al., Stereotaxic Needle Localization and Cytological Diagnosis of Occult Breast Lesions, Annals of Surgery, Nov. 1986, pp. 580-584, vol. 204-No. 5.
Jong-Won Rhie, et al. “Implantation of Cultured Preadipocyte Using ChitosanlAlginate Sponge”, Key Engineering Materials, Jul. 1, 2007, pp. 346-352, XP008159356, ISSN: 0252-1059, DOI: 10.4028/www.scientific.net/KEM.342-343.349, Department of Plastic Surgery, College of Medicine, The Catholic University of Korea, Seoul Korea.
Related Publications (1)
Number Date Country
20120179251 A1 Jul 2012 US
Provisional Applications (3)
Number Date Country
60061588 Oct 1997 US
60077639 Mar 1998 US
60091306 Jun 1998 US
Divisions (2)
Number Date Country
Parent 11108785 Apr 2005 US
Child 12589413 US
Parent 09828806 Apr 2001 US
Child 10627718 US
Continuations (2)
Number Date Country
Parent 12965405 Dec 2010 US
Child 13426061 US
Parent 12589413 Oct 2009 US
Child 12965405 US
Continuation in Parts (2)
Number Date Country
Parent 10627718 Jul 2003 US
Child 11108785 US
Parent 09169351 Oct 1998 US
Child 09828806 US